Paper Details

  1. Home
  2. Paper Details

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.

Author: , BowmanLouise, BraunwaldEugene, CannonChristopher P, ChenFang, CollinsRory, HopewellJemma C, LandrayMartin J, SammonsEmily, StevensWilliam, WallendszusKarl, WiviottStephen D

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This abstract discusses the potential benefits and concerns surrounding anacetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, for reducing cardiovascular events in patients with atherosclerotic vascular disease. It highlights the mixed results of trials on other CETP inhibitors and emphasizes the need for further research to determine its overall effectiveness.
Paper Details　
Original Abstract of the Article :
Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and inc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1706444

データ提供：米国国立医学図書館（NLM）

Anacetrapib: A Potential Oasis in the Desert of Atherosclerotic Vascular Disease

Atherosclerotic vascular disease (ASVD) is a major health concern, characterized by the buildup of plaque in the arteries. Imagine a desert where the arteries are choked with sand, hindering the flow of life-giving blood. This study explores the potential of anacetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, for treating ASVD. It's like finding a hidden oasis in the desert, offering a new pathway to manage this challenging condition.

Anacetrapib: A New Hope in the Desert of ASVD

The researchers investigated the effects of anacetrapib in patients with ASVD. They found that anacetrapib effectively reduced LDL cholesterol levels and increased HDL cholesterol levels. While this is encouraging, previous trials of other CETP inhibitors have shown mixed results, highlighting the complexity of this disease and the need for further research.

Navigating the Desert of ASVD: A Journey of Understanding

This study sheds light on the potential benefits of anacetrapib in treating ASVD, offering a glimpse into a new approach to managing this complex condition. However, further research is needed to confirm its long-term efficacy and safety. By continuing to explore innovative treatments and understanding the intricate mechanisms of ASVD, we can find new pathways to improve the health and well-being of individuals affected by this disease.

Dr.Camel's Conclusion

This study offers a promising oasis in the desert of atherosclerotic vascular disease. Anacetrapib, a CETP inhibitor, shows potential for reducing LDL cholesterol levels and increasing HDL cholesterol levels. However, further research is needed to fully assess its long-term benefits and risks. By continuing to explore innovative treatments and understanding the complexities of ASVD, we can find new ways to navigate the desert of this challenging condition and improve the health of those affected.

Date :
  1. Date Completed 2017-10-04
  2. Date Revised 2023-01-20
Further Info :

Pubmed ID

28847206

DOI: Digital Object Identifier

10.1056/NEJMoa1706444

Related Literature

Article Analysis
・Effective treatment of cholesterol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.